Inebilizumab
- CAS No.
- 1299440-37-1
- Chemical Name:
- Inebilizumab
- Synonyms
- Inebilizumab;Inebilizumab (anti-CD19);Research Grade Inebilizumab;Research Grade Inebilizumab(DHD10802);MEDI 551|||MT-0551|||16C4-aFuc|||VIB-0551;Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer (ACI)
- CBNumber:
- CB18080940
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 74T7185BMM |
| NCI Drug Dictionary | inebilizumab |
| ATC code | L04AA47 |
Inebilizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0535056 | Inebilizumab 99.00% | 1299440-37-1 | 1mg | $260 | 2026-06-04 | Buy |
| ChemScene | CS-0535056 | Inebilizumab 99.00% | 1299440-37-1 | 5mg | $672 | 2026-06-04 | Buy |
| ChemScene | CS-0535056 | Inebilizumab 99.00% | 1299440-37-1 | 10mg | $1078 | 2026-06-04 | Buy |
| ChemScene | CS-0535056 | Inebilizumab 99.00% | 1299440-37-1 | 25mg | $2058 | 2026-06-04 | Buy |
| ChemScene | CS-0535056 | Inebilizumab 99.00% | 1299440-37-1 | 50mg | $3467 | 2026-06-04 | Buy |
Inebilizumab Chemical Properties, Uses, Production
Uses
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1].
in vivo
Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo[2].
| Animal Model: | huCD19/CD20 double Tg mice[2] |
| Dosage: | 0.5, 2, or 10 mg/kg |
| Administration: | Tail vein injection, once |
| Result: | Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages. |
References
[1] Chen D, et al. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J Clin Med. 2016 Nov 24;5(12):107. DOI:10.3390/jcm5120107
[2] Herbst R, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010 Oct;335(1):213-22. DOI:10.1124/jpet.110.168062
Inebilizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Inebilizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19935 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
View Latest Price from Inebilizumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-07 | Inebilizumab
1299440-37-1
|
$157.00-659.00 | 99.1% (SDS-PAGE); 96.2% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Inebilizumab
1299440-37-1
- $157.00-659.00
- 99.1% (SDS-PAGE); 96.2% (SEC-HPLC)
- TargetMol Chemicals Inc.
